Clinical trials: Hydroxychloroquine
Type1 Diabetes Mellitus
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
- Trial name
- TN-22 (NCT03428945)
- Testing
- Hydroxychloroquine
- Where
- 51 sites in United States, Australia and 4 more
- Volunteers
- 273 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pancreatic Cancer
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
This is a randomized phase II trial that will examine the ability of the hydroxychloroquine to improve the clinical activity of a pre-operative regimen of gemcitabine and nab-paclitaxel in subjects with potentially resectable…
- Trial name
- NCT01978184
- Testing
- gemcitabine, abraxane, hydroxychloroquine
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Nathan Bahary, MD
Pre-diabetes
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology…
- Trial name
- NCT01326533
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pittsburgh
Solid Tumor
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Baseline levels of PAR-4 secreted by normal cells are generally inadequate to cause massive apoptosis in cancer cells and drugs that bolster the secretion of PAR-4 would constitute an important therapeutic advance.The apoptosis…
- Trial name
- NCT02232243
- Testing
- Hydroxychloroquine, 200mg twice dailiy, Hydroxychloroquine, 400mg twice daily
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Peng Wang, MD PhD
Rheumatoid Arthritis
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment…
- Trial name
- TEAR (NCT00259610)
- Testing
- methotrexate, sulfasalazine, hydroxychloroquine
- Where
- United States
- Volunteers
- 755 people
- Sponsor
- University of Alabama at Birmingham
COVID-19
Ivermectin for Severe COVID-19 Management
In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause…
- Trial name
- NCT04646109
- Testing
- Ivermectin
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Afyonkarahisar Health Sciences University
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
Coronavirus, Corona Virus Infection
PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine
The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and prophylaxis/treatment in health care workers because…
- Trial name
- NCT04353037
- Testing
- Group 1 HCQ
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- UnitedHealth Group
Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine.
- Conditions
- Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01649947
- Testing
- Paclitaxel, Carboplatin, Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Cancer
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.
- Trial name
- NCT02316340
- Testing
- Vorinostat, Hydroxychloroquine, Regorafenib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer Recurrent
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
Treatment of recurrent oligometastatic prostate cancer may be enhanced by the addition of Hydroxychloroquine to the current treatment regimens.
- Trial name
- NCT04011410
- Testing
- Hydroxychloroquine Sulfate 200Mg Tab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Patrick Hensley
Virus Diseases, Infection Viral
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.
- Conditions
- Virus Diseases, Infection Viral, Corona Virus Infection
- Trial name
- ProPAC-COVID (NCT04322396)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- 8 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Tumor, Solid, Gastrointestinal Cancer
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies.
- Trial name
- NCT05221320
- Testing
- Ulixertinib, Hydroxychloroquine
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- BioMed Valley Discoveries, Inc
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute
Kidney Failure, Chronic, Cardiovascular Disease
Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study
Presence of multiple traditional and nontraditional risk factors of atherosclerosis and cardiovascular disease (CVD) including inflammation in patients with chronic kidney disease (CKD) contribute to high CVD morbidity and…
- Conditions
- Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
- Trial name
- NCT01537315
- Testing
- Hydroxychloroquine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Arkansas
Pancreatic Cancer
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Hydroxychloroquine is approved for the treatment of non-cancerous illnesses such as rheumatoid arthritis and systemic lupus erythematous.
- Trial name
- NCT01273805
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Pancreatitis, Insulin Dependent Diabetes
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT
This will be a pilot, 12-month phase II, open label, randomized, two-arm, single-blinded, placebo-controlled, parallel clinical trial of individuals undergoing TPAIT (Total Pancreatectomy and Autologous Islet Transplantation) for…
- Trial name
- NCT03283566
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
COVID-19, Corona Virus Infection
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients.
- Trial name
- NCT04318444
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Columbia University
COVID-19
COVID-19 PrEP HCW HCQ Study
Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04354870
- Testing
- Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- NYU Langone Health
Rheumatoid Arthritis
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
Primary Objective: To assess the effect of sarilumab in combination with conventional synthetic Disease-Modifying Anti-Rheumatic Drug (csDMARD) and/or monotherapy on participant-reported impact of disease, using the rheumatoid…
- Trial name
- SariPRO (NCT03449758)
- Testing
- SARILUMAB, Azathioprine, Chloroquine
- Where
- 33 sites in France
- Volunteers
- 84 people
- Sponsor
- Sanofi